Pharmacokinetic evaluation of losartan

Bibliography

• Chobanian AV, Bakris GL, Black HR, Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Mancia G, De BG, Dominiczak A, 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007;25:1751-62
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Chrysant GS, Chrysant C, Shiraz M. The treatment of cardiovascular disease continuum: focus on prevention and RAS blockade. Curr Clin Pharmacol 2010;5:89-95
   PubMedGoogle Scholar
• Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Chiu AT, McCall DE, Price WA Jr, In vitro pharmacology of DuP 753. Am J Hypertens 1991;4:282S-7S
   PubMed Web of Science ®Google Scholar
• Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet 2005;44:797-814
   PubMed Web of Science ®Google Scholar
• Yasar U, Forslund-Bergengren C, Tybring G, Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002;71:89-98
   PubMed Web of Science ®Google Scholar
• Li Z, Wang G, Wang LS, Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects. Xenobiotica 2009;39:788-93
   PubMed Web of Science ®Google Scholar
• Kazierad DJ, Martin DE, Blum RA, Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997;62:417-25
   PubMed Web of Science ®Google Scholar
• Christen Y, Waeber B, Nussberger J, Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991;83:1333-42
   PubMed Web of Science ®Google Scholar
• Goldberg MR, Tanaka W, Barchowsky A, Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993;21:704-13
   PubMed Web of Science ®Google Scholar
• Munafo A, Christen Y, Nussberger J, Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992;51:513-21
   PubMed Web of Science ®Google Scholar
• Maillard MP, Wurzner G, Nussberger J, Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther 2002;71:68-76
   PubMed Web of Science ®Google Scholar
• Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008;68:1207-25
   PubMed Web of Science ®Google Scholar
• Vauquelin G, Fierens F, Van L, I. Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. J Hypertens Suppl 2006;24:S23-30
   PubMedGoogle Scholar
• Forclaz A, Maillard M, Nussberger J, Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003;41:31-6
   PubMed Web of Science ®Google Scholar
• Mazzolai L, Maillard M, Rossat J, Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists. Hypertension 1999;33:850-5
   PubMed Web of Science ®Google Scholar
• Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60
   PubMed Web of Science ®Google Scholar
• Pitt B, Poole-Wilson PA, Segal R, Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de ZD, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
   PubMed Web of Science ®Google Scholar
• Konstam MA, Neaton JD, Dickstein K, Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374:1840-8
   PubMed Web of Science ®Google Scholar
• Parving HH, Persson F, Lewis JB, Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46
   PubMed Web of Science ®Google Scholar
• Meier P, Maillard MP, Meier JR, Combining blockers of the renin-angiotensin system or increasing the dose of an angiotensin II receptor antagonist in proteinuric patients: a randomized triple-crossover study. J Hypertens, in press, 2011
   Google Scholar
• Coltamai L, Maillard M, Simon A, Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans. J Hypertens 2010;28:520-6
   PubMed Web of Science ®Google Scholar
• Mohanram A, Zhang Z, Shahinfar S, The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney Int 2008;73:630-6
   PubMed Web of Science ®Google Scholar
• Burnier M, Rutschmann B, Nussberger J, Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993;22:339-47
   PubMed Web of Science ®Google Scholar
• Soffer BA, Wright JT Jr, Pratt JH, Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26:112-7
   PubMed Web of Science ®Google Scholar
• Hoieggen A, Alderman MH, Kjeldsen SE, The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-9
   PubMed Web of Science ®Google Scholar